Disclaimer
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
We are a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. We are listed on Euronext Brussels, headquartered in Ghent, Belgium and also have offices in Zurich, Switzerland.
We embrace diversity and inclusion. You will have the opportunity to work with outstanding business teams and contribute to the success of the company. We strive to provide all our employees with the means to develop their skills and experiences, at every level.
The HR Generalist reports to the HR Manager and will act as an expert for HR operations, payroll & benefits queries, and processes for internal and external partners in Belgium.
The HR Generalist acts as a point of contact for employees with the aim of providing optimal support in the development and execution of the HR policies and processes. Furthermore, the HR Generalist brings organizational and administrative support within one or more HR Domains.
Administrative & Payroll:
Compliance:
Projects:
We offer a full time (100%) contract in a very dynamic and international environment with an attractive salary package at our Ghent office.
If you are interested, please send your resume and motivation to careers@sequanamedical.com
The IT System Administrator needs to ensure the proper functioning of existing IT infrastructures, to maintain them and to make them evolve according to the needs and new technical solutions.
We offer a full time (100%) contract in a very dynamic and international environment with an attractive salary package at our Zürich office.
If you are interested, please send your resume and motivation to careers@sequanamedical.com
The employee is responsible for supporting the execution of Sequana Medical’s clinical studies and programs in line with the company’s clinical development programs, under supervision of the Global Director Clinical Operations.
We offer a part time / full time (80%-100%) contract in a very dynamic and international environment with an attractive salary package at our Ghent office.
If you are interested, please send your resume and motivation to careers@sequanamedical.com
GlobalData NASH Epidemiology Forecast to 2026
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370
Kilgore et al. (2017); Ambrosy et al. (2014)
Ginès et al. (2004) (déclarant que l’ascite réfractaire apparaît chez 5 à 10% des patients souffrant d’ascite)
Runyon et al. (2009)
World Health Organization International Agency for Research on Cancer 2018 (website) (estimated number of new breast and ovarian cases in 2018 (crude rate))
Ayantunde et al. (2006)
Benjamin et al. (2013)
Costanzo et al. (2007)
Kilgore et al. (2017)
Estes et al. (2018)
European Association for the Study of the Liver. EASL clinical practice guideliones on the management of ascites, spontane bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402
The alfapump® is still under clinical investigation in the US and Canada and therefore any statements regarding safety and efficacy do not apply in these territories.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe, the US and Canada.
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (web site)
Lies Vanneste
Director IR
Direct: +32 9 298 2864
Mobile: +32 498 053579
Sequana Medical NV
Technologiepark 122
9052 Zwijnaarde, Belgium